Loading company…
Riskpilot
← Back to search
Sign in
Get full access
PHARMASTRAT CONSULTING APS
APS
Active
CVR 43346318
Ben Websters Vej 32
Activities of holding companies · NACE 6421
Est. 2022
— employees
Watchlist
Share
Download PDF
Full Risika report
Overview
Financials
People & ownership
Related companies
Revenue 2025
DKK -11K
-24% vs 2024
EBITDA margin
100.0%
+24% vs 2024
Equity ratio
94.5%
Financial strength
Net profit 2025
DKK -30K
-647% vs 2024
EBITDA — year on year
DKK millions
0M
0M
1M
1M
1M
0M
2022
0M
0%
2023
0M
0%
2024
0M
0%
2025
Key figures
Annual report 2025
Revenue
DKK -11K
-24%
EBITDA
DKK -11K
+24%
Net profit
DKK -30K
-647%
Total assets
DKK 2,6M
-3%
Equity
DKK 2,5M
-5%
Employees
—
—
Company information
Legal name
PHARMASTRAT CONSULTING APS
CVR number
43346318
Legal form
Anpartsselskab
NACE code
6421 · Activities of holding companies
Founded
23. juni 2022
Share capital
DKK 40.000
Employees
—
VAT registered
Yes
Audit selected
No
Last report
2025-12-31
Financial year
January – December
Signatory rights
Selskabet tegnes af en direktør eller af den samlede direktion
Company purpose
Selskabets formål er at eje kapitalandele i andre virksomheder samt al virksomhed, som efter direktionens skøn har forbindelse hermed
Contact
Address
Ben Websters Vej 32
Phone
+4553765433
Email
pharmastrat2020@gmail.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
Visit risika.com
Explore
Companies in Activities of holding companies
Companies in København
All Denmark companies
Revenue
DKK millions
0M
0M
1M
1M
1M
0M
2022
0M
2023
0M
2024
0M
2025
EBITDA
DKK millions
0M
0M
1M
1M
1M
0M
2022
0M
2023
0M
2024
0M
2025
Income statement
DKK thousands
Item
2022
2023
2024
2025
Revenue
260
-8
-15
-11
Staff expenses
-182
-0
-0
-0
EBITDA
79
-8
-15
-11
Depreciation & amort.
-25
-25
-25
-25
EBIT
54
-33
-40
-36
Net financials
-22
1.804
36
6
Profit before tax
32
1.771
-4
-30
Tax
7
-16
-0
-0
Net profit
25
1.788
-4
-30
Balance sheet
DKK thousands
Item
2022
2023
2024
2025
Total assets
1.457
2.730
2.705
2.614
Equity
907
2.695
2.591
2.471
Long-term debt
0
0
0
0
Short-term debt
534
35
114
143
Total debt
534
35
114
143
Financial ratios
5-year trend
EBITDA margin
-1112000.0%
This company
15.8%
Market median
-7038075% vs market
2022
2025
Equity ratio
94.5%
This company
38.2%
Market median
+147% vs market
2022
2025
Return on equity
-1.2%
This company
18.4%
Market median
-107% vs market
2022
2025
Net profit margin
-2982100.0%
This company
8.1%
Market median
-36816149% vs market
2022
2025
Asset turnover
-0.00×
This company
1.12×
Market median
-100% vs market
2022
2025
Debt / equity
0.06×
This company
0.62×
Market median
+90% vs market
2022
2025
Annual reports & filings
Annual report 2025
Filed via CVR / Virk · Period 2025-01-01 – 2025-12-31
View
PDF
Annual report 2024
Filed via CVR / Virk · Period 2024-01-01 – 2024-12-31
View
PDF
Annual report 2023
Filed via CVR / Virk · Period 2023-01-01 – 2023-12-31
View
PDF
Annual report 2022
Filed via CVR / Virk · Period 2022-01-01 – 2022-12-31
View
PDF
Management
Actively employed in the business
No data on file.
Board of directors
Non-executive oversight
No data on file.
Shareholders
As of last annual report
Shareholder
Type
Ownership
Votes
Since
Nicolas Clément Tipsmark Bouchet
Individual
100.0%
100.0%
2022
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive.
Learn more
.
Company hierarchy
No registered parent or subsidiaries
Board network connections
Board members of PHARMASTRAT CONSULTING APS also hold positions in
0
other companies.
Person
Role here
Other companies